Novo Nordisk A/S
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Novo Nordisk A/S sits in the top decile of US sponsors by registered trial count (#81 of 15,742 sponsors by registered trial count).
Novo Nordisk A/S: 431 sponsored US clinical trials, 34 recruiting.
Novo Nordisk A/S sponsors 431 registered US clinical trials on ClinicalTrials.gov, 34 of them currently recruiting, and 342 completed. 243 of these trials are in Phase 3-4 (later-stage) and 155 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diabetes Mellitus, Type 2, with 48 trials.
Top-decile sponsor footprint
Novo Nordisk A/S ranks in the top decile of sponsors by registered trial count (#81 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
342 of 363 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
431 total, page 9 of 9
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes
NCT00095082
Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes
NCT00097084
Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes
NCT00097279
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
NCT00154427
NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
NCT00095446
Use of Activated Recombinant FVII in Spinal Surgery
NCT00102037
Dose Response to Recombinant Factor VIIa When Administered for Bleed
NCT00104455
Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
NCT00108758
Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes
NCT01497600
Observational Registry of the Treatment of Glanzmann's Thrombasthenia
NCT01476423
Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs
NCT00791895
Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children
NCT00102817
Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency
NCT00056589
Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes
NCT00283751
Comparison of Glycemic Control Achieved With 2 Different Needles
NCT00572052
Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy
NCT00598793
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation
NCT01564563
An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)
NCT01009905
Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
NCT00071448
Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes
NCT01605773
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage
NCT01563445
Trial of NovoSeven® in Haemophilia - Joint Bleeds
NCT00108797
Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis
NCT01561352
Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency
NCT01502124
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation
NCT01562158
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group
NCT01511185
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
NCT01511198
Effect of Growth Hormone in Children With Growth Hormone Deficiency
NCT00262249
A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin
NCT00931476
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes
NCT00065130
Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
NCT01561391
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 94 |
| Phase 2 | 61 |
| Phase 3 | 220 |
| Phase 4 | 23 |
Therapeutic Areas
Where Novo Nordisk A/S enrollment is open (later-stage tilt)
34 recruiting of 431 indexed (8% open); 342 completed (79%).
Phase mix: 243 late (III/IV) vs 155 early (I/II) (later-stage heavy).
Top condition: Diabetes Mellitus, Type 2 (48 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Novo Nordisk A/S: open-pipeline peers nationwide
Peers matched on 431 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
Novo Nordisk A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 431 trials (± recruiting share)
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
- University of Illinois at Chicago · 430 trials · 27% recruiting
- Vanderbilt University · 430 trials · 3% recruiting
- Dartmouth-Hitchcock Medical Center · 427 trials · 12% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 8% recruiting · 305 trials
- Boston Scientific Corporation · 8% recruiting · 280 trials
- United Therapeutics · 8% recruiting · 63 trials
- Hoffmann-La Roche · 8% recruiting · 909 trials
Related
What to do with this Novo Nordisk A/S page
431 registered trials is a research-attention snapshot, not an endorsement of Novo Nordisk A/S or any single study.
- 34 of Novo Nordisk A/S's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diabetes Mellitus, Type 2 is the condition Novo Nordisk A/S studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetes Mellitus, Type 2 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Novo Nordisk A/S pipeline card: 431 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.